PHILIP MOOS
Associate Professor
Pharmacology and Toxicology
- Associate ProfessorPharmacology and Toxicology
RESEARCH INTERESTS
The Moos laboratory is broadly interested in understanding how phenotype influences determinants of disease or conditions. Explicitly, we evaluate gene expression to study cancer drug susceptibility, neuropsychiatric conditions, infectious diseases, and pulmonary fibrosis. Our
scientific approach to these diseases and conditions includes preparing high-quality samples and understanding and interpreting transcriptomic patterns.
Primary cancers generally have defined therapeutic options, but those with relapsed disease often do not have clear therapeutic options. Our precision oncology efforts involve collaborations with other groups at the University of Utah and Huntsman Cancer Institute where we combine
genomics, transcriptomics, and drug sensitivity assay to investigate tumor susceptibilities in patients with relapsed cancer to offer the best therapeutic options for these patients.
Treatments for various neuropsychiatric conditions are frequently rather non-specific; therefore, our approach involves utilizing transcriptomics to improve the understanding of molecular mechanisms that influence behavior and try to manipulate those changes pharmacologically.
While many infectious diseases can have effective therapies, certain combined infections are particularly challenging for unknown reasons. This collaboration with other University of Utah scientists is exploring the nature of these infections using advanced transcriptomic approaches in
human samples. These studies are yielding unexpected outcomes butproviding insights into these complicated disease states.
Chronic inflammatory conditions can result in diseases from fibrosis to cancer. We collaborate with other investigators to understand the overactivation of the immune system in these conditions.
The Moos lab collaborates with many investigators on a variety of projects, mostly those that include transcriptomic components.
GRANTS
- EXTERNAL GRANT OR CONTRACTCRISPR DROPOUT SCREEN IN TRIPLE-NEGATIVE BREAST CANCER PDO MODEL1 Apr 2022 - 31 Mar 2024
- EXTERNAL GRANT OR CONTRACTNational Cancer Institute Director's Challenge: Molecular Taxonomy of Pediatric and Adult Acute LeukemiaUniversity of New Mexico8 Jan 2020 - 31 Dec 2022
- EXTERNAL GRANT OR CONTRACTU54 CA209978-01A1 Resistant Cancer Phenotypes5 Jan 2017 - 31 Dec 2020
- EXTERNAL GRANT OR CONTRACTTRP Channels and Air PollutionNIH/NIEHS8 Jan 2012 - 31 Dec 2017
- EXTERNAL GRANT OR CONTRACTCity of Hope National CoreCITY OF HOPE NATIONAL MEDICAL5 Jan 2007 - 31 Dec 2022
- EXTERNAL GRANT OR CONTRACTINGESTED NANOPARTICLESUS ENVIRONMENTAL PROTECTION AG5 Jan 2007 - 31 Dec 2010
- EXTERNAL GRANT OR CONTRACTROLE OF SELENOPROTEINSNIH NATIONAL CANCER INSTITUTE6 Oct 2005 - 31 Dec 2010
- EXTERNAL GRANT OR CONTRACTTranscellular Leukotriene Biosynthesis: Inflammation and CancerNational Institute of Allergy and Infectious Diseases7 Jan 2002 - 31 Dec 2005